• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    4/21/23 9:06:04 AM ET
    $ADTX
    $AZYO
    $CADL
    $CMPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $ADTX alert in real time by email

    Gainers

    • NovaBay Pharmaceuticals (AMEX:NBY) shares moved upwards by 25.3% to $1.93 during Friday's pre-market session. The company's market cap stands at $3.9 million.
    • Onconova Therapeutics (NASDAQ:ONTX) stock increased by 22.52% to $0.86. The market value of their outstanding shares is at $18.0 million.
    • Aziyo Biologics (NASDAQ:AZYO) stock increased by 21.68% to $2.02. The company's market cap stands at $32.7 million.
    • Cyclo Therapeutics (NASDAQ:CYTH) shares moved upwards by 14.52% to $0.81. The market value of their outstanding shares is at $8.5 million.
    • CytoMed Therapeutics (NASDAQ:GDTC) stock increased by 12.61% to $3.75. The company's market cap stands at $41.0 million.
    • Compass Therapeutics (NASDAQ:CMPX) shares rose 11.51% to $3.1. The market value of their outstanding shares is at $392.1 million.

    Losers

    • Candel Therapeutics (NASDAQ:CADL) shares decreased by 14.9% to $1.2 during Friday's pre-market session. The market value of their outstanding shares is at $34.7 million.
    • Vallon Pharmaceuticals (NASDAQ:VLON) stock decreased by 13.05% to $0.4. The company's market cap stands at $5.3 million.
    • Aditxt (NASDAQ:ADTX) shares decreased by 12.43% to $0.88. The company's market cap stands at $3.7 million.
    • Plus Therapeutics (NASDAQ:PSTV) shares fell 12.0% to $0.27. The market value of their outstanding shares is at $9.5 million. As per the press release, Q1 earnings came out yesterday.
    • Sonnet BioTherapeutics (NASDAQ:SONN) stock decreased by 11.26% to $0.27. The market value of their outstanding shares is at $5.4 million.
    • Vincerx Pharma (NASDAQ:VINC) stock fell 9.1% to $0.91. The company's market cap stands at $19.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTX
    $AZYO
    $CADL
    $CMPX

    CompanyDatePrice TargetRatingAnalyst
    Compass Therapeutics Inc.
    $CMPX
    2/13/2026$15.00Buy
    Craig Hallum
    PLUS THERAPEUTICS Inc.
    $PSTV
    2/3/2026$2.00Buy
    Lake Street
    Compass Therapeutics Inc.
    $CMPX
    1/5/2026Outperform
    William Blair
    Compass Therapeutics Inc.
    $CMPX
    12/3/2025$10.00Mkt Outperform
    Citizens JMP
    Compass Therapeutics Inc.
    $CMPX
    12/3/2025$10.00Buy
    Canaccord Genuity
    Compass Therapeutics Inc.
    $CMPX
    12/3/2025Overweight
    Cantor Fitzgerald
    Candel Therapeutics Inc.
    $CADL
    10/28/2025$15.00Overweight
    Stephens
    PLUS THERAPEUTICS Inc.
    $PSTV
    9/3/2025$5.00Hold → Buy
    D. Boral Capital
    More analyst ratings

    $ADTX
    $AZYO
    $CADL
    $CMPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Sims Andrew John Hugh Macintyre

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    2/27/26 4:08:43 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Hedrick Marc H

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    2/27/26 4:07:51 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Director Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    2/26/26 7:38:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADTX
    $AZYO
    $CADL
    $CMPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

    HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the American Medical Association's (AMA) CPT® (Current Procedural Terminology) Editorial Panel approved a new Category III CPT code to track utilization of convection-enhanced delivery (CED) used in the administration of REYOBIQ for recurrent glioblastoma (rGBM) and pediatric brain cancer (PBC).   "The approved Category III CPT code for convection-enhanced delivery of REYOBIQ in recurrent glioblastoma and pediatric brain cancer – the most

    2/25/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston

    NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at TD Cowen's 46th Annual Health Care Conference, being held on March 2-4, 2026 in Boston, MA. Presentation Details: Date: Tuesday, March 3, 2026 Time: 11:50 AM - 12:20 PM ET Webcast Link: TD Cowen / Candel Presentation A webcast of the presentation will be available by selecting Events and Presentations under the News &

    2/24/26 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Announces Pricing of Public Offering

    NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the pricing of an underwritten public offering of 18,348,624 shares of its common stock at a price to the public of $5.45 per share. The gross proceeds to Candel from the offering are expected to be $100 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about February 23, 2026, subject to customary closing conditions. In addition, Candel has grant

    2/19/26 9:40:00 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADTX
    $AZYO
    $CADL
    $CMPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Compass Therapeutics with a new price target

    Craig Hallum initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $15.00

    2/13/26 8:35:30 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lake Street initiated coverage on Plus Therapeutics with a new price target

    Lake Street initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $2.00

    2/3/26 8:52:26 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    William Blair initiated coverage on Compass Therapeutics

    William Blair initiated coverage of Compass Therapeutics with a rating of Outperform

    1/5/26 8:57:39 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADTX
    $AZYO
    $CADL
    $CMPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    2/26/26 7:38:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Sims Andrew John Hugh Macintyre bought $10,200 worth of shares (20,000 units at $0.51), increasing direct ownership by 42% to 68,138 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    11/5/25 8:30:03 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Director Lenk Robert P bought $53,779 worth of shares (110,000 units at $0.49), increasing direct ownership by 375% to 139,327 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    8/25/25 7:30:05 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $ADTX
    $AZYO
    $CADL
    $CMPX
    SEC Filings

    View All

    SEC Form 8-K filed by Candel Therapeutics Inc.

    8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

    2/23/26 8:00:28 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NovaBay Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    2/20/26 4:24:56 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Candel Therapeutics Inc.

    424B5 - Candel Therapeutics, Inc. (0001841387) (Filer)

    2/20/26 4:16:14 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADTX
    $AZYO
    $CADL
    $CMPX
    Leadership Updates

    Live Leadership Updates

    View All

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Compass Therapeutics Announces Key Leadership Appointments

    BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointments of Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, both effective as of January 1, 2026. "We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "Arjun's world-class expertise in on

    1/5/26 8:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

    Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary, CNSide Diagnostic LLC's, Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory developed test (LDT). Recent accomplishments include expansion of the CNSide manufacturing footprint,

    10/21/25 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $ADTX
    $AZYO
    $CADL
    $CMPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Vincerx Pharma Inc.

    SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/14/24 3:39:40 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vincerx Pharma Inc.

    SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/14/24 11:57:03 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $AZYO
    $CADL
    $CMPX
    Financials

    Live finance-specific insights

    View All

    Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

    HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the American Medical Association's (AMA) CPT® (Current Procedural Terminology) Editorial Panel approved a new Category III CPT code to track utilization of convection-enhanced delivery (CED) used in the administration of REYOBIQ for recurrent glioblastoma (rGBM) and pediatric brain cancer (PBC).   "The approved Category III CPT code for convection-enhanced delivery of REYOBIQ in recurrent glioblastoma and pediatric brain cancer – the most

    2/25/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization

    HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today provides a business update and highlights REYOBIQ clinical progress and CNSide US commercialization. "Our 2 key goals in 2026 are CNSide commercial scale-up and REYOBIQ pivotal trial readiness," said Dr. Marc H. Hedrick, President & Chief Executive of Plus Therapeutics. "Our recently completed upsized $15 million offering will fuel faster progress in these core areas of the business and extend our cash runway through 2027." Overview of anticipated

    1/22/26 7:45:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

    HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, January 22, 2026 before the market open. Plus Therapeutics' management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. Webcast and Conference Call Date/Time:Thursday, January 22, 2026 @ 9:00 AM ETWebcast:https://event.choruscall.com/mediaframe/webcast.html?webcastid=x5QZCyIkParticipant Dial-in:1-888-349-0106   Please di

    1/21/26 4:15:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care